Jeffrey Bluestone, Sonoma co-founder and CEO (Tessa Therapeutics via YouTube)

Jef­frey Blue­stone re­cruits a trio of bio­phar­ma vets to the start­up team at Sono­ma — while adding $30M to the launch round

Jef­frey Blue­stone’s start­up in the Bay Area just added a pack­et of ven­ture mon­ey to its cash re­serves. But more im­por­tant­ly, the ex-chief of the Park­er In­sti­tute for Can­cer Im­munother­a­py re­cruit­ed sev­er­al more ex­pe­ri­enced vets to the ex­ec­u­tive team that will dri­ve new drugs to con­quer au­toim­mune dis­eases like di­a­betes.

On the mon­ey side, Sono­ma Ther­a­peu­tics to­day an­nounced that its syn­di­cate came up with an ex­tra $30 mil­lion for the launch round, bring­ing the to­tal to $70 mil­lion. The cash came from a broad group of in­vestors, led by Rick Klaus­ner’s Lyell and ARCH. Here’s the rest of the crew: 8VC, Life­Force Cap­i­tal, Lil­ly Asia Ven­tures Bio­sciences, Oc­ta­gon Cap­i­tal, Alexan­dria Ven­ture In­vest­ments, the JDRF T1D Fund and ad­di­tion­al undis­closed in­vestors.

That will help fund a team that now in­cludes:

— Leonard Drag­one, the new chief med­ical of­fi­cer. Drag­one is com­ing in from J&J, where he was VP for ear­ly clin­i­cal de­vel­op­ment in in­fec­tious dis­eases. Be­fore that, he had been the ther­a­peu­tic area lead for au­toim­mu­ni­ty, in­flam­ma­tion and oph­thal­mol­o­gy at Mer­ck and ear­li­er com­plet­ed a stint at Genen­tech.

— Se­jal Hall joined the com­pa­ny from Au­dentes, which was re­cent­ly bought out by Astel­las. She steps in as VP, pro­gram, port­fo­lio and al­liance man­age­ment, a role she held ear­li­er at De­nali.

— Ab­b­Vie vet­er­an Su­san Lacy is al­so join­ing the team as head of dis­cov­ery. She worked at the phar­ma gi­ant for the past 20 years.

Blue­stone left the helm of PI­CI and his post at UC San Fran­cis­co to start a biotech that will fo­cus on Tregs in halt­ing au­toim­mune as­saults. Now, in­stead of dri­ving im­mune re­spons­es to van­quish can­cer cells, he’ll be hit­ting the brakes to stop dis­eases like di­a­betes.

Blue­stone’s promi­nence in the West Coast biotech scene has earned some high-pro­file sup­port­ers, in­clud­ing Klaus­ner, the ex­ec­u­tive chair­man at Lyell who al­so chairs the board at Sono­ma.

And he’s aim­ing high. In a re­cent in­ter­view, he told me:

We’ll end up with a cheap­er ther­a­py on­ly hav­ing to do things once, hope­ful­ly, be­cause it’s built on the plat­form of what evo­lu­tion has al­ready cre­at­ed: reg­u­la­to­ry cells as brakes in the im­mune sys­tem.

Health­care Dis­par­i­ties and Sick­le Cell Dis­ease

In the complicated U.S. healthcare system, navigating a serious illness such as cancer or heart disease can be remarkably challenging for patients and caregivers. When that illness is classified as a rare disease, those challenges can become even more acute. And when that rare disease occurs in a population that experiences health disparities, such as people with sickle cell disease (SCD) who are primarily Black and Latino, challenges can become almost insurmountable.

David Meek, new Mirati CEO (Marlene Awaad/Bloomberg via Getty Images)

Fresh off Fer­Gene's melt­down, David Meek takes over at Mi­rati with lead KRAS drug rac­ing to an ap­proval

In the insular world of biotech, a spectacular failure can sometimes stay on any executive’s record for a long time. But for David Meek, the man at the helm of FerGene’s recent implosion, two questionable exits made way for what could be an excellent rebound.

Meek, most recently FerGene’s CEO and a past head at Ipsen, has become CEO at Mirati Therapeutics, taking the reins from founding CEO Charles Baum, who will step over into the role of president and head of R&D, according to a release.

Jacob Van Naarden (Eli Lilly)

Ex­clu­sives: Eli Lil­ly out to crash the megablock­buster PD-(L)1 par­ty with 'dis­rup­tive' pric­ing; re­veals can­cer biotech buy­out

It’s taken 7 years, but Eli Lilly is promising to finally start hammering the small and affluent PD-(L)1 club with a “disruptive” pricing strategy for their checkpoint therapy allied with China’s Innovent.

Lilly in-licensed global rights to sintilimab a year ago, building on the China alliance they have with Innovent. That cost the pharma giant $200 million in cash upfront, which they plan to capitalize on now with a long-awaited plan to bust up the high-price market in lung cancer and other cancers that have created a market worth tens of billions of dollars.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

FDA hands ac­cel­er­at­ed nod to Seagen, Gen­mab's so­lo ADC in cer­vi­cal can­cer, but com­bo stud­ies look even more promis­ing

Biopharma’s resident antibody-drug conjugate expert Seagen has scored a clutch of oncology approvals in recent years, finding gold in what are known as “third-gen” ADCs. Now, another of their partnered conjugates is ready for prime time.

The FDA on Monday handed an accelerated approval to Seagen and Genmab’s Tivdak (tisotumab vedotin-tftv, or “TV”) in second-line patients with recurrent or metastatic cervical cancer who previously progressed after chemotherapy rather than PD-(L)1 systemic therapy, the companies said in a release.

Rafaèle Tordjman (Jeito Capital)

Con­ti­nu­ity and di­ver­si­ty: Rafaèle Tord­j­man's women-led VC firm tops out first fund at $630M

For a first-time fund, Jeito Capital talks a lot about continuity.

Rafaèle Tordjman had spotlighted that concept ever since she started building the firm in 2018, promising to go the extra mile(s) with biotech entrepreneurs while pushing them to reach patients faster.

Coincidentally, the lack of continuity was one of the sore spots listed in a report about the European healthcare sector published that same year by the European Investment Bank — whose fund is one of the LPs, alongside the American pension fund Teacher Retirement System of Texas and Singapore’s Temasek, to help Jeito close its first fund at $630 million (€534 million). As previously reported, Sanofi had chimed in €50 million, marking its first investment in a French life sciences fund.

Dave Lennon, former president of Novartis Gene Therapies

Zol­gens­ma patent spat brews be­tween No­var­tis and Re­genxbio as top No­var­tis gene ther­a­py ex­ec de­parts

Regenxbio, a small licensor of gene therapy viral vectors spun out from the University of Pennsylvania, is now finding itself in the middle of some major league patent fights.

In addition to a patent suit with Sarepta Therapeutics from last September, Novartis, is now trying to push its smaller partner out of the way. The Swiss biopharma licensed Regenxbio’s AAV9 vector for its $2.1 million spinal muscular atrophy therapy Zolgensma.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.

Time for round 2: Il­lu­mi­na-backed VC snags $325M for its next fund

Illumina Ventures closed off its second investment fund with a total commitment of $325 million, offering fresh fuel to back a slate of startups that have already included a smorgasbord of companies, covering everything from diagnostics to biotech drug development and genomics.

Fund II brings the total investment under Illumina Ventures’ oversight to $560 million, which has been focused on early-stage companies. And it has a transatlantic portfolio that includes SQZ, Twist and Encoded Therapeutics.

Volker Wagner (L) and Jeff Legos

As Bay­er, No­var­tis stack up their ra­dio­phar­ma­ceu­ti­cal da­ta at #ES­MO21, a key de­bate takes shape

Ten years ago, a small Norwegian biotech by the name of Algeta showed up at ESMO — then the European Multidisciplinary Cancer Conference 2011 — and declared that its Bayer-partnered targeted radionuclide therapy, radium-223 chloride, boosted the overall survival of castration-resistant prostate cancer patients with symptomatic bone metastases.

In a Phase III study dubbed ALSYMPCA, patients who were treated with radium-223 chloride lived a median of 14 months compared to 11.2 months. The FDA would stamp an approval on it based on those data two years later, after Bayer snapped up Algeta and christened the drug Xofigo.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.

Raju Mohan, Ventyx Biosciences CEO

Months af­ter a mam­moth raise, Ven­tyx Bio­sciences dips back in­to ven­ture well

Several months after emerging from what CEO Raju Mohan called “quiet mode” with a mammoth $114 million raise, Ventyx Biosciences is now making its plans for the clinic loud and clear.

The California-based immune modulation player kicked the week off with a $51 million Series B, while also naming some key hires ahead of its big clinical push.

The CMO slot is going to Jörn Drappa, former CMO at Viela Bio before it was bought out by Horizon Therapeutics earlier this year. The AstraZeneca vet stayed on at Horizon for a while as executive VP of R&D before making the jump to Ventyx.